Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vanda Pharmaceuticals Inc VNDA

Healthcare Biotechnology
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in... see more

Recent & Breaking News (NDAQ:VNDA)

Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference

PR Newswire September 8, 2022

VANDA PHARMACEUTICALS ANNOUNCES NOTICE OF OPPORTUNITY FOR AN FDA HEARING ON THE sNDA FOR HETLIOZ® IN JET LAG DISORDER

PR Newswire September 7, 2022

Vanda Pharmaceuticals Reports Second Quarter 2022 Financial Results

PR Newswire August 3, 2022

Vanda Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 3, 2022

PR Newswire July 27, 2022

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Vanda Pharmaceuticals Inc.

Newsfile June 30, 2022

Vanda Pharmaceuticals Announces Participation in the Jefferies 2022 Global Healthcare Conference

PR Newswire June 2, 2022

Vanda Pharmaceuticals Announces Presentations at SLEEP 2022

PR Newswire May 31, 2022

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Vanda Pharmaceuticals Inc.

Newsfile May 26, 2022

Vanda Pharmaceuticals Announces Presentations at DDW 2022

PR Newswire May 19, 2022

Vanda Pharmaceuticals Reports First Quarter 2022 Financial Results

PR Newswire May 5, 2022

Vanda Pharmaceuticals Announces Participation in the BofA Securities 2022 Healthcare Conference

PR Newswire May 4, 2022

Vanda Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 5, 2022

PR Newswire April 28, 2022

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

PR Newswire February 23, 2022

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

PR Newswire February 17, 2022

Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis

PR Newswire February 4, 2022

Vanda Pharmaceuticals Settles HETLIOZ® Patent Litigation with MSN

PR Newswire January 14, 2022

Vanda Pharmaceuticals Announces Participation at November 2021 Investor Conferences

PR Newswire November 10, 2021

Vanda Pharmaceuticals Reports Third Quarter 2021 Financial Results

PR Newswire November 3, 2021

Vanda Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 3, 2021

PR Newswire October 27, 2021

Vanda Pharmaceuticals Announces Participation at Evercore ISI's Catalyst Day

PR Newswire October 14, 2021